Pharmaceutical ProductCached Profile
WATCHMAN ACCESS SYSTEM
Active Ingredients (Generic):Unmapped
Therapeutic Area: WATCHMAN_IC
LIFETIME PROMOTIONAL SPEND
$517,202
General Payments Aggregated (2021–2024)
Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Interventional Study to Investigate the Effects of Percutaneous Closure of the Left Atrial Appendage on Atrial and Brain Natriuretic Peptide Secretion
UNKNOWNPhase NANCT01522911
Stand-Alone Left Atrial Appendage Occlusion for throMboembolism Prevention in Nonvalvular Atrial fibrillatioN DiseasE Registry (SALAMANDER)
UNKNOWNPhase N/ANCT05144958
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
RECRUITINGPhase N/ANCT06686485
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. JORGE ROMEROMedical Doctor$51,000
Dr. BRYON GENTILE IIMedical Doctor$33,494
Dr. PAUL MAHONEYMedical Doctor$30,364
Dr. RAGHAVA GOLLAPUDIMedical Doctor$29,720
Dr. HYUN-HO JAMIE KIMMedical Doctor$26,094
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2024
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for WATCHMAN ACCESS SYSTEM...